Typical and atypical forms of B-cell chronic lymphocytic leukemia show different clinical features, cytogenetic abnormalities and prognosis

1998 ◽  
Vol 5 (1) ◽  
pp. 43
Author(s):  
&NA;
2009 ◽  
Vol 33 (10) ◽  
pp. 1319-1327 ◽  
Author(s):  
Agnieszka Bojarska-Junak ◽  
Iwona Hus ◽  
Sylwia Chocholska ◽  
Ewa Wąsik-Szczepanek ◽  
Małgorzata Sieklucka ◽  
...  

2020 ◽  
Vol 116 ◽  
pp. 104524
Author(s):  
Tatiana Zhevak ◽  
Tatiana Shelekhova ◽  
Nina Chesnokova ◽  
Olga Tsareva ◽  
Anna Chanturidze ◽  
...  

2006 ◽  
Vol 12 (4) ◽  
pp. 187-192
Author(s):  
F. Scamardella ◽  
M. Maconi ◽  
L. Albertazzi ◽  
B. Gamberi ◽  
L. Gugliotta ◽  
...  

Author(s):  
Alessandro Pileri ◽  
Carlotta Baraldi ◽  
Alessandro Broccoli ◽  
Roberto Maglie ◽  
Annalisa Patrizi ◽  
...  

2001 ◽  
Vol 194 (11) ◽  
pp. 1639-1648 ◽  
Author(s):  
Andreas Rosenwald ◽  
Ash A. Alizadeh ◽  
George Widhopf ◽  
Richard Simon ◽  
R. Eric Davis ◽  
...  

The most common human leukemia is B cell chronic lymphocytic leukemia (CLL), a malignancy of mature B cells with a characteristic clinical presentation but a variable clinical course. The rearranged immunoglobulin (Ig) genes of CLL cells may be either germ-line in sequence or somatically mutated. Lack of Ig mutations defined a distinctly worse prognostic group of CLL patients raising the possibility that CLL comprises two distinct diseases. Using genomic-scale gene expression profiling, we show that CLL is characterized by a common gene expression “signature,” irrespective of Ig mutational status, suggesting that CLL cases share a common mechanism of transformation and/or cell of origin. Nonetheless, the expression of hundreds of other genes correlated with the Ig mutational status, including many genes that are modulated in expression during mitogenic B cell receptor signaling. These genes were used to build a CLL subtype predictor that may help in the clinical classification of patients with this disease.


Sign in / Sign up

Export Citation Format

Share Document